PIPAC is a new and promising technique for the intraperitoneal administration of chemotherapy. It can be used in patients with various peritoneal cancer metastases. It is mainly a palliative treatment, but there is some neoadjuvant treatment potential. We have operated on 41 patients with various intra-abdominal cancers. PIPAC was performed every 6 weeks. The indication was extension of peritoneal carcinomatosis beyond the criteria for cytoreductive surgery and HIPEC. The effect was evaluated according to the peritoneal cancer index, the peritoneal regression grading score and the amount of ascites. Complications were classified according to the Clavien-Dindo system. We have performed 100 PIPAC procedures. There were two major complications, classified as Clavien Dindo III (2%). The number of procedures varied from 1 to 6. Five patients switched to cytoreductive surgery and HIPEC, and one was indicated for the watch and wait strategy due to total regression according to PRGS. Three patients are still continuing treatment. The others stopped treatment mainly because of progression of the disease and loss of metastases. We observed a reduction in ascites production soon after PIPAC application. PIPAC is a safe and well-tolerated treatment modality. It is mainly a palliative treatment that can improve the quality of life by reducing the production of ascites, but in about 10% of cases, it can reduce the extent of the disease and allow for further radical treatment.
PIPAC（腹腔内加压气溶胶化疗）是一种新型且前景广阔的腹腔内化疗给药技术，适用于多种腹膜癌转移患者。该技术主要作为姑息治疗手段，同时具备一定的新辅助治疗潜力。我们对41例各类腹腔内癌症患者进行了手术治疗，每6周实施一次PIPAC治疗。适应症为腹膜癌扩散程度超出细胞减灭术联合腹腔热灌注化疗标准范围的患者。治疗效果通过腹膜癌指数、腹膜消退分级评分及腹水量进行评估，并发症依据Clavien-Dindo系统进行分类。 我们共实施了100次PIPAC治疗，其中发生两例严重并发症（Clavien Dindo III级，占比2%）。患者接受治疗次数为1至6次不等：5例患者转为接受细胞减灭术联合腹腔热灌注化疗；1例患者因PRGS评估显示完全消退，转为观察等待策略；3例患者仍在继续治疗。其余患者终止治疗的主要原因是疾病进展及转移灶消失。我们观察到PIPAC治疗后腹水生成迅速减少。 PIPAC是一种安全且耐受性良好的治疗方式，主要通过减少腹水生成改善患者生活质量，属于姑息治疗范畴。但在约10%的病例中，该技术能够有效控制疾病进展，为后续根治性治疗创造条件。
肿瘤(癌症)患者之家